HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 price objective on the biotechnology company’s stock. ATNM has been the subject of a number of other research reports. StockNews.com lowered Actinium Pharmaceuticals from a […]
StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) to a sell rating in a research note published on Wednesday morning. ATNM has been the subject of several other reports. HSBC began coverage on Actinium Pharmaceuticals in a research report on Wednesday, September 6th. They set a buy rating and a $11.60 price target […]